Compare QUALCOMM, Inc. (QCOM) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
QUALCOMM, Inc. vs TG Therapeutics Inc — how do they compare? QUALCOMM, Inc. trades at $173.5 (market cap $185.94B), while TG Therapeutics Inc trades at $54.77 (market cap $8.36B). The key difference: QUALCOMM, Inc. is far larger — about 22.2× TG Therapeutics Inc's market cap, and QUALCOMM, Inc. pays a 2.11% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| QCOM | TGTX | |
|---|---|---|
Market Cap | $185.94B | $8.36B |
Sector | Technology | Health |
52-Week High | $251.10 | $59.06 |
52-Week Low | $124.07 | $26.94 |
Enterprise Value | $192.90B | $8.57B |
Dividend Yield | 2.11% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Qualcomm (QCOM) trades at $174.09, up 3.17% today, with a bullish technical signal and strong analyst consensus. Recent earnings show mixed results, beating estimates in Q4 2025 and Q1 2026 but missing in Q2 2026. The company maintains robust cash flow from operations at $14.01B in 2025 and is diversifying into AI and automotive markets, though smartphone demand softness poses near-term challenges.
The outlook remains positive with a $199.35 consensus price target, supported by AI growth initiatives. Key risks include competitive pressure from Nvidia in PC chips and margin pressures. Institutional sentiment is cautiously optimistic, with 43% buy ratings, but investors should monitor execution in new markets and smartphone segment recovery.
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The stock shows strong profitability with a net income margin of 55.22% and ROE of 100.28%, though recent quarters have seen earnings misses. Revenue growth is robust, with 2026 guidance raised to $950 million for BRIUMVI, and buyout rumors have fueled positive sentiment.
The outlook for TGTX is positive driven by BRIUMVI's commercial success and pipeline catalysts, but risks include earnings volatility, high valuation multiples, and competitive pressures. Institutional accumulation supports upside, yet investors should weigh execution risks against growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About QUALCOMM, Inc.
Qualcomm develops and licenses wireless technology and designs chips for smartphones. The company's key patents revolve around CDMA and OFDMA technologies, which are standards in wireless communications that are the backbone of all 3G and 4G networks. The firm is a leader in 5G network technology as well. Qualcomm's IP is licensed by virtually all wireless device makers. The firm is also the world's largest wireless chip vendor, supplying nearly every premier handset maker with leading-edge processors. Qualcomm also sells RF-front end modules into smartphones and chips into automotive and Internet of Things markets.
Read more on QCOM →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
